Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection
- 22 February 2021
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (8), 2037-2039
- https://doi.org/10.1080/10428194.2021.1888378
Abstract
Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disease involving immunoglobulin G (IgG), IgM, or IgA, and/or components of the complement system targeting red blood cell membrane antigens ...This publication has 15 references indexed in Scilit:
- Covid-19 and autoimmunityAutoimmunity Reviews, 2020
- Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre seriesBritish Journal of Haematology, 2020
- IgA‐mediated autoimmune hemolytic anemiaAmerican Journal of Hematology, 2019
- Warm antibody autoimmune hemolytic anemiaHematology, 2016
- A randomized and double‐blind controlled trial evaluating the safety and efficacy of rituximab for warm auto‐immune hemolytic anemia in adults (the RAIHA study)American Journal of Hematology, 2016
- Immune Hemolysis: Diagnosis and Treatment RecommendationsSeminars in Hematology, 2015
- A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemiaBritish Journal of Haematology, 2013
- Cut‐off value of red‐blood‐cell‐bound IgG for the diagnosis of Coombs‐negative autoimmune hemolytic anemiaAmerican Journal of Hematology, 2008
- Epidemiology of autoimmune diseases in DenmarkJournal of Autoimmunity, 2007
- IgA red cell autoantibodies and autoimmune hemolysisTransfusion, 1997